Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2

Human Gene Therapy

Volumn 19, Issue 5, 2008, Pages 496-510

  Heemskerk, Bianca ^a   Liu, Ke ^a,b   Dudley, Mark E ^a   Johnson, Laura A ^a   Kaiser, Andrew ^a   Downey, Stephanie ^a   Zheng, Zhili ^a   Shelton, Thomas E ^a   Matsuda, Kant ^a   Robbins, Paul F ^a   Morgan, Richard A ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; FLUDARABINE; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ANTIBODY; INTERLEUKIN 2 TRANSDUCED TUMOR INFILTRATING LEUKOCYTE; MESSENGER RNA; OKT 3; STEROID;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER GENE THERAPY; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; FEVER; FLOW CYTOMETRY; GENE INSERTION; GENETIC ENGINEERING; HEMATOPOIETIC STEM CELL; HUMAN; IN VITRO GENE TRANSFER; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTOSIS; MELANOMA; METASTASIS; RASH; TELOMERE; TRANSGENE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE;

ADOPTIVE TRANSFER; ADULT; CELL LINE; CELL MOVEMENT; CELL SURVIVAL; FEMALE; GENETIC ENGINEERING; HUMANS; INTERLEUKIN-2; LYMPHOCYTES; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; TRANSDUCTION, GENETIC; TRANSGENES; TREATMENT OUTCOME;

EID: 44349117909     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2007.0171     Document Type: Article

References (33)

1. + regulatory T cells in cancer patients. Blood 107, 2409-2414.
2. + T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174, 2591-2601.
3. CAVALIERI, S., CAZZANIGA, S., GEUNA, M., MAGNANI, Z., BORDIGNON, C., NALDINI, L., and BONINI, C. (2003). Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood 102, 497-505.
4. DUDLEY, M.E., WUNDERLICH, J.R., ROBBINS, P.F., YANG, J.C., HWU, P., SCHWARTZENTRUBER, D.J., TOPALIAN, S.L., SHERRY, R., RESTIFO, N.P., HUBICKI, A.M., ROBINSON, M.R., RAFFELD, M., DURAY, P., SEIPP, C.A., ROGERS-FREEZER, L., MORTON, K.E., MAVROUKAKIS, S.A., WHITE, D.E., and ROSENBERG, S.A. (2002a). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854.
5. DUDLEY, M.E., WUNDERLICH, J.R., YANG, J.C., HWU, P., SCHWARTZENTRUBER, D.J., TOPALIAN, S.L., SHERRY, R.M., MARINCOLA, F.M., LEITMAN, S.F., SEIPP, C.A., ROGERS-FREEZER, L., MORTON, K.E., NAHVI, A., MAVROUKAKIS, S.A., WHITE, D.E., and ROSENBERG, S.A. (2002b). A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 25, 243-251.
6. DUDLEY, M.E., WUNDERLICH, J.R., SHELTON, T.E., EVEN, J., and ROSENBERG, S.A. (2003). Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26, 332-342.
7. DUDLEY, M.E., WUNDERLICH, J.R., YANG, J.C., SHERRY, R.M., TOPALIAN, S.L., RESTIFO, N.P., ROYAL, R.E., KAMMULA, U., WHITE, D.E., MAVROUKAKIS, S.A., ROGERS, L.J., GRACIA, G.J., JONES, S.A., MANGIAMELI, D.P., PELLETIER, M.M., GEA-BANACLOCHE, J., ROBINSON, M.R., BERMAN, D.M., FILIE, A.C., ABATI, A., and ROSENBERG, S.A. (2005). Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23, 2346-2357.
8. ELLIS, J., and YAO, S. (2005). Retrovirus silencing and vector design: Relevance to normal and cancer stem cells? Curr. Gene Ther. 5, 367-373.
9. + T cells. J. Exp. Med. 202, 907-912.
10. + T cells. J. Clin. Invest. 115, 1616-1626.
11. + T cells enter reactive lymph nodes and kill dendritic cells. Nat. Immunol. 8, 743-752.
12. HODES, R.J., HATHCOCK, K.S., and WENG, N.P. (2002). Telomeres in T and B cells. Nat. Rev. Immunol. 2, 699-706.
13. HSU, C., HUGHES, M.S., ZHENG, Z., BRAY, R.B., ROSENBERG, S.A., and MORGAN, R.A. (2005). Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. J. Immunol. 175, 7226-7234.
14. + T cells independently of its effects on survival and proliferation. J. Immunol. 175, 8003-8010.
15. + T lymphocytes. Nature 421, 852-856.
16. LAMERS, C.H., GRATAMA, J.W., POUW, N.M., LANGEVELD, S.C., KRIMPEN, B.A., KRAAN, J., STOTER, G., and DEBETS, R. (2005). Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: Implications for loss of transgene expression. Hum. Gene Ther. 16, 1452-1462.
17. LIU, K., and ROSENBERG, S.A. (2001). Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J. Immunol. 167, 6356-6365.
18. LIU, K., and ROSENBERG, S.A. (2003). Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent. J. Immunother. 26, 190-201.
19. LORD, J.D., MCINTOSH, B.C., GREENBERG, P.D., and NELSON, B.H. (2000). The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the transactivation domain of Stat5. J. Immunol. 164, 2533-2541.
20. LOTZE, M.T., MATORY, Y.L., ETTINGHAUSEN, S.E., RAYNER, A.A., SHARROW, S.O., SEIPP, C.A., CUSTER, M.C., and ROSENBERG, S.A. (1985). In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J. Immunol. 135, 2865-2875.
21. MORGAN, R.A., DUDLEY, M.E., WUNDERLICH, J.R., HUGHES, M.S., YANG, J.C., SHERRY, R.M., ROYAL, R.E., TOPALIAN, S.L., KAMMULA, U.S., RESTIFO, N.P., ZHENG, Z., NAHVI, A., DE VRIES, C.R., ROGERS-FREEZER, L.J., MAVROUKAKIS, S.A., and ROSENBERG, S.A. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129.
22. + T cells. J. Exp. Med. 198, 569-580.
23. + tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105, 241-250.
24. ROBBINS, P.F., DUDLEY, M.E., WUNDERLICH, J., EL GAMIL, M., LI, Y.F., ZHOU, J., HUANG, J., POWELL, D.J., JR., and ROSENBERG, S.A. (2004). Cutting edge: Persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173, 7125-7130.
25. ROSENBERG, S.A., LOTZE, M.T., YANG, J.C., AEBERSOLD, P.M., LINEHAN, W.M., SEIPP, C.A., and WHITE, D.E. (1989). Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210, 474-484.
26. RUFER, N., MIGLIACCIO, M., ANTONCHUK, J., HUMPHRIES, R.K., ROOSNEK, E., and LANSDORP, P.M. (2001). Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential. Blood 98, 597-603.
27. SMITH, F.O., GOFF, S.L., KLAPPER, J.A., LEVY, C., ALLEN, T., MAVROUKAKIS, S.A., and ROSENBERG, S.A. (2007). Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody. J. Immunother. 30, 130.
28. THERASSE, P., ARBUCK, S.G., EISENHAUER, E.A., WANDERS, J., KAPLAN, R.S., RUBINSTEIN, L., VERWEIJ, J., VAN GLABBEKE, M., VAN OOSTEROM, A.T., CHRISTIAN, M.C., and GWYTHER, S.G. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, 205-216.
29. WALDMANN, T.A. (2006). The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6, 595-601.
30. + memory T cells. Nature 441, 890-893.
31. + T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. U.S.A. 99, 16168-16173.
32. + regulatory T cells. Nat. Med. 11, 1238-1243.
33. ZHOU, J., SHEN, X., HUANG, J., HODES, R.J., ROSENBERG, S.A., and ROBBINS, P.F. (2005). Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175, 7046-7052.